[go: up one dir, main page]

EA200800710A1 - TREATMENT OF KIDNEY INSUFFICIENCY, BURNS, RAS AND SPINAL BRAIN DAMAGES BY SELECTIVE MODULES OF THE ANDROGEN RECEPTOR - Google Patents

TREATMENT OF KIDNEY INSUFFICIENCY, BURNS, RAS AND SPINAL BRAIN DAMAGES BY SELECTIVE MODULES OF THE ANDROGEN RECEPTOR

Info

Publication number
EA200800710A1
EA200800710A1 EA200800710A EA200800710A EA200800710A1 EA 200800710 A1 EA200800710 A1 EA 200800710A1 EA 200800710 A EA200800710 A EA 200800710A EA 200800710 A EA200800710 A EA 200800710A EA 200800710 A1 EA200800710 A1 EA 200800710A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
androgen receptor
treating
ras
burns
Prior art date
Application number
EA200800710A
Other languages
Russian (ru)
Inventor
Джеймс Т. Долтон
Дуэйн Д. Миллер
Original Assignee
Юниверсити Оф Теннесси Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Теннесси Рисерч Фаундейшн filed Critical Юниверсити Оф Теннесси Рисерч Фаундейшн
Publication of EA200800710A1 publication Critical patent/EA200800710A1/en
Priority to EA201101574A priority Critical patent/EA019849B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/32—Tin compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение обеспечивает: 1) способ лечения субъекта, страдающего от или предрасположенного к заболеванию почек или нарушению функции почек; 2) способ лечения субъекта, страдающего от раны или уменьшение частоты, или смягчение силы раны у субъекта; 3) способ лечения субъекта, страдающего от ожога или уменьшение частоты, или смягчение силы ожога у субъекта, содержащий стадию введения упомянутому субъекту соединения селективного модулятора андрогенового рецептора (SARM); 4) способ лечения субъекта, страдающего от повреждения спинного мозга, введением субъекту селективного модулятора андрогенового рецептора (SARM) и/или аналога, производного, изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксила, пролекарства, полиморфа, примеси или кристаллической формы упомянутого SARM соединения или их любой комбинации.This invention provides: 1) a method of treating a subject suffering from or predisposed to kidney disease or impaired renal function; 2) a method of treating a subject suffering from a wound or reducing the frequency or softening the strength of the wound in the subject; 3) a method of treating a subject suffering from a burn or reducing the frequency or mitigating the burn power of a subject, comprising the step of administering to said subject a compound of a selective androgen receptor modulator (SARM); 4) a method for treating a subject suffering from spinal cord injury by administering to the subject a selective androgen receptor modulator (SARM) and / or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxyl, prodrug, polymorph, impurity or a crystalline form of said SARM compound, or any combination thereof.

EA200800710A 2005-08-31 2006-08-28 TREATMENT OF KIDNEY INSUFFICIENCY, BURNS, RAS AND SPINAL BRAIN DAMAGES BY SELECTIVE MODULES OF THE ANDROGEN RECEPTOR EA200800710A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201101574A EA019849B1 (en) 2006-08-28 2011-11-25 Method of treating, suppressing, inhibiting or reducing incidents of symptoms associated with kidney disease: hypogonadism and unvoluntary weight loss

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71239005P 2005-08-31 2005-08-31
PCT/US2006/033490 WO2007027582A2 (en) 2005-08-31 2006-08-28 Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
EA200800710A1 true EA200800710A1 (en) 2008-06-30

Family

ID=37809404

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800710A EA200800710A1 (en) 2005-08-31 2006-08-28 TREATMENT OF KIDNEY INSUFFICIENCY, BURNS, RAS AND SPINAL BRAIN DAMAGES BY SELECTIVE MODULES OF THE ANDROGEN RECEPTOR

Country Status (14)

Country Link
US (1) US20070066568A1 (en)
EP (2) EP1931199A4 (en)
JP (1) JP2009506119A (en)
KR (1) KR101388087B1 (en)
CN (1) CN101299920A (en)
AU (1) AU2006285026B2 (en)
BR (1) BRPI0617117A2 (en)
CA (1) CA2621189A1 (en)
DK (1) DK2425715T3 (en)
EA (1) EA200800710A1 (en)
ES (1) ES2453981T3 (en)
IL (1) IL189843A0 (en)
PT (1) PT2425715E (en)
WO (1) WO2007027582A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
CN1726034A (en) * 2002-10-15 2006-01-25 田纳西大学研究基金会 Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
EP2054049B1 (en) 2006-08-24 2016-04-13 University of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
KR20170001736A (en) * 2007-09-11 2017-01-04 지티엑스, 인코포레이티드 Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
JP5604807B2 (en) * 2008-05-21 2014-10-15 日産自動車株式会社 Fuel hose
CN102458399B (en) 2009-04-30 2014-04-23 美国中西部大学 New pharmaceutical uses of centhaquin
JP2013516501A (en) * 2010-01-11 2013-05-13 ジーティーエックス・インコーポレイテッド How to treat meibomian gland dysfunction
US9511077B2 (en) * 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) * 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
FR2982261B1 (en) * 2011-11-04 2014-06-13 Galderma Res & Dev NOVEL AMIDES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
LT2872482T (en) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. A method of treating breast cancers with selective androgen receptor modulator (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR102138526B1 (en) * 2014-01-14 2020-07-28 엘지전자 주식회사 Apparatus and Method for Digital Device providing quick control menu
WO2016061615A1 (en) 2014-10-22 2016-04-28 Chavah Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHODS OF REDUCING MAMMARY DENSITY TO MAMMOGRAPHY AND / OR RISK OF BREAST CANCER
EP4364811A3 (en) * 2018-05-03 2024-07-10 Midwestern University Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
JP2022535827A (en) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ Pharmaceutical formulations and systems for the delivery of androgenic agents and aromatase inhibitors, and methods for use
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
EP4277613A4 (en) * 2021-01-15 2024-11-20 University of Tennessee Research Foundation PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BREAST CANCER AND METHODS OF USE THEREOF
US20240293322A1 (en) 2021-06-23 2024-09-05 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
US20250170091A1 (en) * 2023-10-03 2025-05-29 Veru, Inc. Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
WO1989007110A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
ATE113607T1 (en) 1988-01-28 1994-11-15 Polygen Holding Corp POLYPEPTIDE COMPOUNDS WITH GROWTH HORMONE RELEASING ACTIVITY.
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (en) 1989-10-13 2000-08-16 스튜어트 엘.왓트 Erythropoietin isoforms and preparation method thereof and pharmaceutical composition containing it
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
TR200100149T2 (en) 1998-07-06 2001-10-22 Bristol-Myers Squibb Company Biphenyl-sulfonamides as dual angiotensin endothelin receptor antagonists
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
EP1401801B1 (en) * 2000-08-24 2006-11-02 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
EA007921B1 (en) * 2001-12-06 2007-02-27 Джи Ти Икс, ИНК. Treating muscle wasting with selective androgen receptor modulators
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
WO2003074449A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
JP2006505563A (en) * 2002-10-15 2006-02-16 ジーティーエックス・インコーポレイテッド Treatment of obesity with selective androgen receptor modulators
CN1732011A (en) 2002-12-30 2006-02-08 泊达研究基金会 Method of treatment for central nervous system injury
TW200530181A (en) * 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
EA011306B8 (en) * 2004-06-07 2012-10-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Selective androgen receptor modulators and methods of use thereof
EP2054049B1 (en) * 2006-08-24 2016-04-13 University of Tennessee Research Foundation Substituted acylanilides and methods of use thereof

Also Published As

Publication number Publication date
KR20080045726A (en) 2008-05-23
KR101388087B1 (en) 2014-04-25
US20070066568A1 (en) 2007-03-22
AU2006285026A1 (en) 2007-03-08
WO2007027582A2 (en) 2007-03-08
EP2425715A1 (en) 2012-03-07
EP1931199A2 (en) 2008-06-18
CA2621189A1 (en) 2007-03-08
DK2425715T3 (en) 2014-04-28
PT2425715E (en) 2014-04-14
IL189843A0 (en) 2008-08-07
WO2007027582A3 (en) 2007-10-25
AU2006285026B2 (en) 2012-08-09
ES2453981T3 (en) 2014-04-09
EP2425715B1 (en) 2014-03-05
JP2009506119A (en) 2009-02-12
CN101299920A (en) 2008-11-05
BRPI0617117A2 (en) 2011-07-12
EP1931199A4 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
EA200800710A1 (en) TREATMENT OF KIDNEY INSUFFICIENCY, BURNS, RAS AND SPINAL BRAIN DAMAGES BY SELECTIVE MODULES OF THE ANDROGEN RECEPTOR
EA201391319A1 (en) CANCER TREATMENT METHOD USING 3- (5-AMINO-2-METHYL-4-OXO-4H-HINAZOLIN-3-IL) PIPERIDIN-2,6-DIONA
WO2005115361A3 (en) Androgen receptor modulators and method of treating disease using the same
CY1123426T1 (en) METHOD FOR OBTAINING MEGLUMINE SALT CRYSTALS OF 1-(5,6-DICHLORO-1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLE-4-CARBOXYLIC ACID
EA201590345A1 (en) METHODS OF CANCER TREATMENT USING 3- (4 - ((4- (MORFOLINOMETHYL) BENZYL) OXY) -1-OXIOIZINDOLIN-2-IL) PIPERIDIN-2,6-DIONA
EA201101507A1 (en) METHODS OF TREATMENT OF SOLID TUMORS
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MY133624A (en) Thio-substituted indole acetic acid derivatives for the treatment of respiratory disease
EA201490269A1 (en) NEW DERIVATIVE 1,2,3,4-TETRAHYDROCHINOLINE SUITABLE FOR TREATMENT OF DIABETES
EA201000808A1 (en) INDOL CONNECTIONS AND METHODS OF TREATMENT OF VISCERAL PAIN
UA100132C2 (en) Isoxazolo-pyridine derivatives
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
MX368368B (en) Indole and indazole compounds as an inhibitor of cellular necrosis.
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
EA201790653A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
TW200616953A (en) Indole, indazole or indoline derivatives
WO2007025005A3 (en) Sustained release formulations of nalbuphine
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
EA201001524A1 (en) Desacetylases B Inhibitors Based on Hydroxamide
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
NZ597866A (en) Therapeutic lactams
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
EA018079B1 (en) Use of indole derivatives as nurr-1 activators for treating parkinson's disease